Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study

Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study

<p>Abstract</p> <p>Background</p> <p>Whether paricalcitol (PCT) reduces proteinuria in the presence of intensified inhibition of Renin-Angiotensin-System (RAS) is poorly studied. We evaluated the antiproteinuric effect of PCT in non-dialysis chronic kidney disease (CKD)...

Full description

Bibliographic Details
Main Authors:	De Nicola Luca, Conte Giuseppe, Russo Domenico, Gorini Antonio, Minutolo Roberto
Format:	Article
Language:	English
Published:	BMC 2012-11-01
Series:	BMC Nephrology
Subjects:	Angiotensin converting enzyme inhibitor Angiotensin II receptor blocker Renin inhibitor Paricalcitol Chronic kidney disease Proteinuria
Online Access:	http://www.biomedcentral.com/1471-2369/13/150

Similar Items

A high sodium intake reduces antiproteinuric response to renin–angiotensin–aldosterone system blockade in kidney transplant recipients
by: Elena Monfá, et al.
Published: (2016-09-01)

Impact of renin-angiotensin system inhibitors on the survival of patients with rectal cancer
by: Marcin Zeman, et al.
Published: (2022-07-01)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
by: Seok Hui Kang, et al.
Published: (2023-05-01)

Renin-angiotensin system blockers and COVID-19
by: Emmanuelle Vidal-Petiot, et al.
Published: (2021-06-01)

Survival Benefit of Renin-Angiotensin System Blockers in Critically Ill Cancer Patients: A Retrospective Study
by: Driss Laghlam, et al.
Published: (2023-06-01)

Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
by: Jenny I. Shen, et al.
Published: (2017-06-01)

The renin-angiotensin system and its blockers
by: Igić Rajko, et al.
Published: (2014-01-01)

Medicinal chemistry of the renin-angiotensin system /
by: Timmermans, P. B. M. W. M., et al.
Published: (1994)

Angiotensins and rheumatoid arthritis
by: N. M. Savushkina, et al.
Published: (2019-01-01)

Impact of Renin‐Angiotensin System Inhibitors on Long‐Term Clinical Outcomes of Patients With Coronary Artery Spasm
by: Byoung Geol Choi, et al.
Published: (2016-07-01)

Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
by: Jordan Loader, et al.
Published: (2022-06-01)

The dual blockade of the renin-angiotensin system in Internal Medicine: after ONTARGET trial
by: F. Rondoni, et al.
Published: (2013-05-01)

Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic
by: Simon B. Gressens, et al.
Published: (2021-02-01)

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
by: Juan Meng, et al.
Published: (2020-01-01)

Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension
by: Karl Andersen
Published: (2009-03-01)

Assessment of optimal renin-angiotensin-system inhibition strategy in Asian patients with STEMI after primary myocardial revascularization
by: Hye-Jin Park, et al.
Published: (2022-01-01)

Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension
by: Sonali R. Gnanenthiran, et al.
Published: (2022-09-01)

Effects of Renin-Angiotensin System Inhibitors on Renal Expression of Renalase in Sprague-Dawley Rats Fed With High Salt Diet
by: Yang Wang, et al.
Published: (2015-11-01)

The renin–angiotensin–aldosterone-system and right heart failure in congenital heart disease
by: Stine Andersen, et al.
Published: (2016-06-01)

Long-term use of renin-angiotensin-system inhibitors after acute myocardial infarction is not associated with survival benefits: Analysis of data from the Korean acute myocardial infarction registry-national institutes of health registry
by: Chan Soon Park, et al.
Published: (2022-08-01)

Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia
by: Daniela-Carmen Ababei, et al.
Published: (2023-09-01)

Antiproteinuric effects of antihypertensive agents in non-diabetic hypertensive population
by: Jovic Zorica, et al.
Published: (2008-09-01)

The influence of renin angiotensin aldosterone system blockers on asymmetric dimethylarginine levels in patients with chronic glomerulonephritis
by: Heleniak Zbigniew, et al.
Published: (2016-12-01)

How to potentialize the effect of renin-angiotensin-aldosterone system inhibitors?
by: D.D. Ivanov
Published: (2021-09-01)

Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors
by: Elena-Mihaela Cordeanu, et al.
Published: (2020-10-01)

Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study
by: Francisco J. de Abajo, et al.
Published: (2021-05-01)

Local Angiotensin-Converting Enzyme 2 Gene Expression in Kidney Allografts Is Not Affected by Renin-Angiotensin-Aldosterone Inhibitors
by: Monika Cahova, et al.
Published: (2021-03-01)

Direct Renin Inhibitor is Better than Angiotensin II Receptor Blocker for Intrarenal Arterioles
by: Yohko Nagai, et al.
Published: (2016-08-01)

Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry
by: Fabio Angeli, et al.
Published: (2022-01-01)

Regulation of Male Fertility by the Renin-Angiotensin System
by: Marta Gianzo, et al.
Published: (2020-10-01)

Capacities of laboratory diagnosis in the assessment of the activity of the renin-angiotensin-aldosterone system
by: M L Maksimov
Published: (2010-06-01)

Renin-angiotensin system inhibitors combined with cisplatin exacerbate cisplatin-induced nephrotoxicity in mice
by: Takumi Tsuji, et al.
Published: (2022-04-01)

Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
by: David S. Fedson, et al.
Published: (2020-06-01)

Final results of BIRCOV trial (ARB, ACEI, DRi in COVID-19)
by: D.D. Ivanov, et al.
Published: (2021-09-01)

The impact of Renin-Angiotensin System Inhibitors on bone fracture risk: a nationwide nested case-control study
by: Kwang Min Kim, et al.
Published: (2024-01-01)

The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus
by: O. K. Vikulova, et al.
Published: (2020-08-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Renin–Angiotensin Inhibitor, Captopril, Attenuates Growth of Patient-Derived Colorectal Liver Metastasis Organoids
by: Georgina E. Riddiough, et al.
Published: (2024-03-01)

Beta-Blocker and Renin–Angiotensin System Inhibitor Combination Therapy in Patients with Acute Myocardial Infarction and Prediabetes or Diabetes Who Underwent Successful Implantation of Newer-Generation Drug-Eluting Stents: A Retrospective Observational Registry Study
by: Yong Hoon Kim, et al.
Published: (2020-10-01)

RENIN-ANGIOTENSIN SYSTEM IN REGULATION OF HEMATOPOIESIS
by: M. L. Kanaeva, et al.
Published: (2018-02-01)